Share Twitter LinkedIn Facebook Email Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.
Edetek’s CONFORM Platform: Streamlining Clinical Data Management in Oncology Trials General 3 Mins Read
High-Dose Chemotherapy for Recurrent Germ Cell Tumors: ASCO 2024 Study Results – Hedyeh Ebrahimi, MD – City of Hope ASCO Annual Meeting 2 Mins Read